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We have used an infectious cDNA clone of equine arteritis virus (EAV) and reverse genetics technology to further characterize the
neutralization determinants in the GP5 envelope glycoprotein of the virus. We generated a panel of 20 recombinant viruses, including 10
chimeric viruses that each contained the ORF5 (which encodes GP5) of different laboratory, field, and vaccine strains of EAV, a chimeric
virus containing the N-terminal ectodomain of GP5 of a European strain of porcine reproductive and respiratory syndrome virus, and 9
mutant viruses with site-specific substitutions in their GP5 proteins. The neutralization phenotype of each recombinant chimeric/mutant strain
of EAV was determined with EAV-specific monoclonal antibodies and EAV strain-specific polyclonal equine antisera and compared to that of
their parental viruses from which the substituted ORF5 was derived. The data unequivocally confirm that the GP5 ectodomain contains
critical determinants of EAV neutralization. Furthermore, individual neutralization sites are conformationally interactive, and the interaction
of GP5 with the unglycosylated membrane protein M is likely critical to expression of individual epitopes in neutralizing conformation.
Substitution of individual amino acids within the GP5 ectodomain usually resulted in differences in neutralization phenotype of the
recombinant viruses, analogous to differences in the neutralization phenotype of field strains of EAVand variants generated during persistent
infection of EAV carrier stallions.
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Introduction includes nine open reading frames (ORFs; Snijder, 2001;Equine viral arteritis (EVA) is a respiratory and repro-
ductive disease of horses that occurs throughout the world
(Timoney and McCollum 1993; Timoney et al., 1986,
1987). Equine arteritis virus (EAV), the causative agent of
EVA, is an enveloped, positive-stranded RNAvirus (Snijder,
2001). EAV is the prototype virus in the family Arterivir-
idae, genus Arterivirus in the order Nidovirales (Cavanagh,
1997). The EAV genome is approximately 12.7 kb and0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.12.015
* Corresponding author. Department of Pathology, Microbiology and
Immunology, School of Veterinary Medicine, University of California, One
Shields Avenue, Davis, CA 95616. Fax: +1-530-752-3349.
E-mail address: ubbalasuriya@ucdavis.edu (U.B.R. Balasuriya).Snijder and Meulenberg, 1998). The two most 5V-proximal
ORFs (1a and 1b) occupy approximately three-quarters of
the genome and encode two replicase polyproteins (1a and
1ab; de Vries et al., 1997; Snijder, 2001; Snijder and
Meulenberg, 1998). The remaining seven ORFs (2a, 2b,
and 3–7) are in the 3V-proximal quarter of the genome and
encode seven structural proteins (de Vries et al., 1992;
Snijder et al., 1999; Wieringa et al., 2003). The EAV particle
is 40–60 nm in diameter with an icosahedral core (diameter
25–35 mm) that consists of the nonsegmented RNA ge-
nome and the nucleocapsid protein N (14 kDa; encoded by
ORF7). The EAV envelope contains two principal proteins,
specifically, the GP5 major envelope glycoprotein (30–44
kDa; encoded by ORF5) and the unglycosylated membrane
Table 1
Recombinant strains of EAV
Virus strain Origin of ORF5 inserta Specific amino
acid changes in
GP5 ectodomain
A45 A45 N/Ab
Chimeric strains of EAV
5r10B4 DEM10B4.3
(neutralization resistant
variant/deletion mutantc,
laboratory strain)
see Fig. 2a
A45.C2 PRRSV/EAV 30
chimera
A45 virus GP5
ectodomain (amino acids
1–114) is replaced with
European PRRSV GP5
N-terminal ectodomain
(amino acids 1–64)
A45-80.4 A45 amino acids 52–79 are
deleted
5rUCD UCD (laboratory strain) see Fig. 2a
5r6D10 EM6D10 (neutralization
resistant variant,d
laboratory strain)
5rVAC MLV Vaccine
5rKY84 KY84 (field isolate)
5rIL93 IL-93 (field isolate)
5rCA95 CA95G (field isolate)
5rWA97 WA97 (field isolate)
5rATCC ATCC (ATCC VR-796)
Chimeric strains of EAV with site-specific substitutions in GP5
5rATCC D49N ATCC 49 D > N
5rATCC K61Q ATCC 61 K > Q
5rATCC T67A ATCC 67 T > A
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proteins form a disulfide-linked heterodimer that is critical
for their maturation and for virus infectivity (de Vries et al.,
1995; Snijder et al., 2003). In addition, the EAV envelope
contains a heterotrimer of three minor membrane glycopro-
teins designated as GP2b, GP3, and GP4 (25, 36–42, and
28 kDa; encoded by ORFs 2b, 3, and 4, respectively;
Wieringa et al., 2003) and an unglycosylated envelope
protein E (8 kDa; encoded by ORF2a; Snijder et al., 1999).
There is only one serotype of EAV; however, field strains
differ in their virulence and neutralization phenotype (Bala-
suriya et al., 1997, 1998, 1999a, 1999b, 2002; Hedges et al.,
1999; McCollum and Timoney 1999; McCollum et al.,
1999; Patton et al., 1999; Timoney and McCollum, 1993).
Animals that recover from EAV infection or those that are
vaccinated with either inactivated or attenuated strains of
EAV develop neutralizing antibodies and are resistant to
subsequent challenge with EAV (Doll et al., 1957, 1968;
McCollum 1986). The GP5 protein expresses the known
neutralization determinants of the virus (Balasuriya et al.,
1993, 1995a, 1995b, 1997; Chirnside et al., 1995, Deregt et
al., 1994, Glaser et al., 1995). We previously identified four
neutralization sites (A–D) in the amino-terminal ectodo-
main of GP5 by comparative amino acid sequence analyses
of a large number of neutralization-resistant viral variants
and field isolates of EAV (Balasuriya et al., 1995a, 1995b,
1997). We also recently have demonstrated that authentic
post-translational modification and conformational matura-
tion of recombinant GP5 occurs only in the presence of the
M protein, and that this interaction is necessary for induc-
tion of anti-EAV neutralizing antibodies in mice and horses
(Balasuriya et al., 2000, 2002).
The availability of an EAV reverse genetics system
allowed us for the first time to directly assess the influence
on virus neutralization of specific changes in the GP5
sequence while keeping the sequence of the rest of the viral
genome constant and thus excluding the influence of varia-
tion in other viral proteins. In this report, we definitively
confirm that the GP5 ectodomain contains the major neutral-
ization epitopes of EAV, and that amino acids within the
proposed four major neutralization sites of GP5 contribute to
the formation of both linear and conformational epitopes in
the amino-terminal ectodomain of the GP5 glycoprotein of
EAV. The data clearly show that the neutralization phenotype
of a virus derived from an infectious cDNA clone was altered
by changing either the entire GP5 or specific amino acids
within the amino-terminal ecotodomain of this protein.
5rATCC E71D ATCC 71 E > D
5rATCC D79N ATCC 79 D > N
5rATCC A85S ATCC 85 A > S
5rATCC N81D ATCC 81 N > D
5rUCD D49N UCD 49 D > N
5rVAC 046SDM MLV vaccine 100 G > S, 104 G > D,
and 106 V > M
a Parental virus from which the ORF5 was swapped into the pA45 plasmid.
b Not applicable.
c Balasuriya et al., 1997.
d Balasuriya et al., 1995a.Results and discussion
Generation of GP5 chimeric and mutant viruses
To characterize the neutralization determinants of EAV, a
panel of 20 recombinant viruses was produced using the
EAV infectious cDNA clone pA45 (Dobbe et al., 2001) asthe backbone as described under Material and methods
(Table 1). The pA45 clone is a derivative of the pEAV030
infectious cDNA clone of EAV (van Dinten et al., 1997).
This panel included 10 chimeric viruses that each contained
the ORF5 of a different laboratory, field, or modified live
virus (MLV) vaccine strain of EAV, a single chimeric virus
that contained the N-terminal ectodomain of GP5 of a
European strain of Porcine reproductive and respiratory
syndrome virus (PRRSV; Dobbe et al., 2001), and 9
recombinant viruses with individual site-specific nucleotide
(nt) substitutions in ORF5 (Figs. 1, 2a, and b and Table 1).
In vitro transcripts derived from chimeric or mutated
genomic cDNA clones were transfected into BHK-21 cells
by electroporation. An immunofluorescence staining assay
for expression of EAV nonstructural (nsp3) and structural
Fig. 1. Flow diagram outlining construction of the full-length chimeric virus constructs that include ORF5 from different strains of EAV in the background of
the infectious cDNA clone of pA45 (Dobbe et al., 2001).
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RNA confirmed that in vitro transcripts were infectious
(data not shown). The cells transfected with each recombi-
nant transcript showed 90–100% cytopathic effect (CPE)
after 72–120 h, and virus stocks were made from these
tissue culture fluids (TCF). To demonstrate the genetic
stability of each recombinant virus, viral RNAwas extracted
from the TCF and ORF5 and flanking regions of ORF4 and
6 were directly sequenced to obtain the consensus sequence.
Most recombinant viruses were genetically stable and main-
tained their neutralization phenotype after repeated cell
culture passage (see below).
Neutralization phenotype of the GP5 chimeric viruses
A panel of well-characterized monoclonal antibodies
(MAbs) and polyclonal antisera to EAV (Table 2) was used
to compare the neutralization phenotype of each of the 11
chimeric viruses (each with a unique GP5; Fig. 2a) with that
of the A45 virus derived from an infectious cDNA clone
(Tables 3a and b). The data confirm that the ectodomain of
GP5 is critical to the neutralization of EAV. For example, the
5r10B4 chimeric virus that lacks amino acids 62–101 of the
GP5 ectodomain was not neutralized by any of the MAbs
( < 32), nor by two of the polyclonal equine antisera ( < 8)
that neutralized the A45 virus. Similarly, a chimeric virus
A45.C2 (Dobbe et al., 2001) in which the EAV GP5
ectodomain was replaced by the ectodomain of the
corresponding PRRSV protein was not neutralized by any
of the MAbs nor by four of the polyclonal equine antisera. A
GP5 ectodomain deletion mutant (A45-80.4; Snijder et al.,2003) that lacks amino acids 52–79, including the single
GP5 N-glycosylation site (Asn-56) of the A45 virus, was
not neutralized by one of the polyclonal antisera (anti-GP5/
M) that neutralized the A45 virus to high titer. Further, the
A4-80.4 deletion mutant was neutralized to a significantly
lower titer by four other polyclonal equine sera as compared
to the A45 virus. Thus, the GP5 ectodomain contains major
neutralization sites of EAV, although the fact that viruses
that lack neutralization sites B (amino acid 61) and portions
of neutralization sites C (amino acids 67–90) and D (amino
acids 99–106) were neutralized to variable titers by some of
the polyclonal equine antisera confirms the presence of
other minor neutralizing epitopes on EAV. These data are
consistent with a recent study that demonstrated that a
deletion mutant of EAV that lacked the immunodominant
region of GP5 (amino acids 66–112) induced neutralizing
antibodies in ponies, but convalescent sera from these
ponies only weakly neutralized two other strains of EAV
(Castillo-Olivares et al., 2003). Thus, neutralization site C
(amino acids 67–90) contains the major neutralizing epito-
pes of EAV that are recognized by horses although, as
described below, there likely is considerable conformational
interaction of the four neutralization sites (A–D) in the
amino-terminal ectodomain of GP5.
The substitution of ORF5 in the pA45 cDNA clone with
the ORF5 derived from individual laboratory, field, and
MLV vaccine strains of EAV usually altered the neutraliza-
tion phenotype of the A45 virus into that of the parental
virus from which the substituted ORF5 was derived, al-
though there were some important exceptions (Tables 3a
and b). For example, although all chimeric viruses with
Table 2
Monoclonal and polyclonal antisera to EAV
Antibody EAV strain/
protein used
for immunization
Protein specificity/
epitope location
(amino acid # and [site])
Monolconal antibodies
5G11a,b. UCD GP5/102 and 104 [D]
6D10a,b UCD GP5/99 [D]
7E5a,b UCD GP5/102 [D]
9F2a,b UCD GP5/NDc [D]
10F11a,b UCD GP5/ND [D]
10H4a,b UCD GP5/102 and 103 [D]
1H7d EM6D10 GP5/49 [A]
1H9d EM6D10 GP5/69 [C]
5E8d EM6D10 GP5/61 [B]
6A2d EM6D10 GP5/69 [C]
7D4d EM6D10 GP5/69 [C]
10B4d EM6D10 GP5/62-101 deleted
[C and D]
3E2e UCD N
12A4f recombinant nsp1 nsp1
Equine antisera
GP5/Mg EAVATCC GP5 and
M protein heterodimer
as a recombinant
vaccine
(pVR100-GP5/M VRP)
GP5 and M proteins
GP5/M+ post
challenge with
EAVKY84g
pVR100-GP5/M VRP
and EAVKY84
polyclonal
EAVKY84g EAVKY84 polyclonal
EAVIL93e EAVIL93 polyclonal
MLV vaccinee MLV vaccine (ARVAC) polyclonal
EAVNVSLf EAVNVSL polyclonal
EAV030Hh EAV030H recombinant
virus
polyclonal
EAVKY53e EAVVBS53i polyclonal
Control serum
NVSLh
N/Aj N/A
Control serum
UCDk
N/A N/A
a Balasuriya et al., 1993.
b Balasuriya et al., 1995a 1995b.
c Not determined.
d Balasuriya et al., 1997.
e MacLachlan et al., 1999.
f Wagner et al., 2003.
g Balasuriya et al., 2002.
h Commercial serum from National Veterinary Services Laboratory.
i Virulent Bucyrus strain of EAV.
j Not applicable.
k Balasuriya et al., 1999a, 1999b.
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5r6D10, and 5r10B4) had a similar neutralization phenotype
as that of the parental virus (UCD, EM6D10, and
DEM10B4.3, respectively) from which their ORF5 was
derived, these three chimeric viruses were all resistant to
neutralization by MAb 1H7, whereas their parental viruses
were neutralized by this MAb. MAb 1H7 recognizes a
conformation-dependent epitope at amino acid 49 (site A)
of the GP5 protein (Balasuriya et al., 1997) and all of thesechimeric viruses have an aspartic acid residue at this
position as do their parental viruses. The chimeric viruses
differ from their respective parents in that their M protein is
derived from the A45 virus, which also is not neutralized by
MAb 1H7. Thus, the failure of MAb 1H7 to neutralize these
three chimeric viruses indicates that another virus protein,
likely the M protein, must interact with GP5 to ensure
presentation of the epitope at site A in neutralizing confor-
mation. We previously have shown that the M protein is
critical to conformational maturation of GP5 (Balasuriya et
al., 2000), however, substitution of either the entire ORF6
(which encodes the M protein) or specific nucleotides in
ORF6 of recombinant viruses will be required to demon-
strate unequivocally that the M protein influences the
expression of some conformation-dependent neutralization
epitopes in the GP5 protein.
The MAbs used in this study recognize both linear and
conformation-dependent epitopes localized to amino acids
49, 61, 69, 99, 102, 103, and 104 of the GP5 protein. These
amino acids largely were conserved among the various
viruses (Table 2 and Fig. 2; Balasuriya et al., 1995a,
1995b, 1997), and the neutralization phenotype of most of
the parental and their respective chimeric viruses with the
MAbs was similar to that of the A45 virus (Table 3a). There
were important differences, however, which confirm the
conformational interaction of neutralization sites A–D in
the GP5 ectodomain. For example, the GP5 protein of the
MLV vaccine and its chimeric virus (5rVAC) had an amino
acid substitution (as compared to A45) at position 104 (Asp
> Gly) and were consistently neutralized to a lower titer by
MAb 5G11 which recognizes an epitope formed by amino
acids 102 and 104 (Table 3a). The amino acid at position
102 was not changed in the 5rVAC virus, but the substitu-
tion at 104 (Gly) was sufficient to alter the neutralization
phenotype of this virus. In contrast, the 5rKY84 recombi-
nant virus was unaltered at positions 102 and 104, but had
multiple amino acid substitutions in neutralization sites B
(61) and C (79 and 81) and was neutralized by MAbs 5G11
to the same titer as 5rVAC. This suggests that amino acid
substitutions in sites B and C exert a conformational
influence on neutralization site D. This conformational
influence exerted by sites B and C is further confirmed by
MAb 10H4 (recognizes an epitope at amino acids 102 and
103) which neutralized 5rVAC to the same titer as the
parental A45 virus (4096), but neutralized the 5rKY84
recombinant virus (which is unaltered at positions 102 and
103) to a lower titer (1024).
Further evidence of the conformational interaction of the
various neutralization sites of EAV (A–D) was evident from
results obtained with MAbs 1H9, 6A2, and 7D4. These
three MAbs recognize the same or overlapping conforma-
tion-dependent epitope(s) formed by amino acid 69 and
other amino acids in this region (Balasuriya et al., 1997).
Amino acid substitutions such as Lys > Gln or Lys > Glu at
position 61 (5rKY84, 5rIL93, and 5rCA95) or Thr > Glu at
position 67 (5rWA97) influenced the neutralization by these
Fig. 2. (a) Aligned deduced amino acid sequence of the N-terminal ectodomain of the GP5 proteins of laboratory and field strains of EAV, MLV vaccine, and
recombinant viruses (A45.C2 and A45-80.4) derived from the pA45 infectious cDNA clone. ORF5 from MLV vaccine and each field strain of EAV was
substituted into the pA45 clone to make the individual chimeric viruses (e.g. 5rATCC, 5rUCD, etc.). All amino acid sequences are compared to the A45 virus
sequence derived from the pA45 infectious cDNA clone of EAV (Dobbe et al., 2001; van Dinten et al., 1997). The signal (S), conserved (C1), and variable (V1)
regions, as well as the critical neutralization sites (A, B, C, and D) in the GP5 envelope protein are indicated above the sequences. The GP5 N-terminal
ectodomain (amino acids 1–114) was replaced by the GP 5 N-terminal ectodomain (amino acids 1–64) of European PRRSV in A45.C2 recombinant virus.
Gaps introduced for maximum matching of PRRSV GP5 N-terminal ectodomain are indicated by ‘‘-’’. Dots indicate the same amino acid as in the aligned
sequence at the top. Letters indicate the amino acid substitutions at each site. Similar amino acids that are not shown in the figure are indicated by ‘‘x‘‘. Deleted
amino acids are indicated by ‘‘^’’. The predicted N-linked glycosylation sites in the GP5 protein are underlined. The respective conserved and variable N-linked
glycosylation sites are indicated by ‘‘*’’ and ‘‘x’’. (b) Aligned deduced amino acid sequence of the critical neutralization region of the GP5 proteins to illustrate
the specific amino acid substitutions that were introduced by site-directed mutagenesis. The substitutions are indicated by bold letters as compared to the
5rATCC, 5rVAC, and 5rUCD strains of EAV. Virus names are indicated at the left-hand side.
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and 69 is confirmed by the 5rKY84 virus which has amino
acid substitutions at both of these positions (Lys > Gln-61
and Leu > Pro-69) yet is still neutralized by MAb 6A2 (Fig.
2a and Table 3a). In contrast, MAb 6A2 failed to neutralize
the 5rVAC virus, which has only a single substitution at
position 69 (Leu > Pro). Furthermore, the substitution of
amino acid 67 (Thr > Glu) in the 5rWA97 virus may have
allowed it to escape neutralization by MAb 6A2, suggesting
that there also is a conformational interaction between
amino acids 67 and 69. Together, these data indicate that
amino acid substitutions in neutralization sites B and C can
exert conformational changes on distant neutralization epit-
opes; for example, amino acid substitutions at 61 and 67 can
alter the epitope at position 69 recognized by MAbs 1H9
and 7D4, resulting in the resistance to neutralization of the
5rKY84, 5rIl93, and 5rCA95 viruses to these two MAbs
(Fig. 2a and Table 3a). Similarly, the chimeric viruses with
different GP5 proteins from field isolates and MLV vaccine
strains of EAV were neutralized to different titers byindividual polyclonal horse antisera (Table 3b), and the
GP5 proteins of these viruses had amino acid substitutions
within neutralization sites B and C as compared to the A45
virus (Fig. 2a). In summary, amino acid substitutions at
amino acids 61 (site B) and 67–90 (site C) of the GP5
protein influence the expression of conformational neutral-
izing epitopes, and similar changes are likely critical to
generating antigenic variation among field strains of EAV.
Neutralization phenotype of viruses with site-specific
substitutions in GP5
To further evaluate the significance of individual amino
acid residues in the four major neutralization sites in the N-
terminal ectodomain of GP5, we introduced nucleotide
substitutions specifying single amino acid changes in the
GP5 ectodomain into chimeric infectious cDNA clones
containing ORF5 of the ATCC, UCD, and MLV vaccine
strains of EAV (Table 1). MAbs and polyclonal antisera
usually neutralized individual recombinant viruses to the
Table 3a
Neutralization titersa of monoclonal antibodies against parental and chimeric strains of EAV
a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 TCID50 of virus.
Significant differences in neutralization phenotype as compared to the A45 virus are boxed. The chimeric viruses with different neutralization phenotype from
their respective parental viruses are shown within the hatched box.
b Parental—original virus strain.
c Chimera—chimeric virus with ORF5 from the respective parental virus inserted into the pA45 infectious cDNA clone of EAV.
d
MAb to the nucleocapsid (N) protein of EAV was used as a negative control.
e MAb to the nonstructural protein 1 (nsp1) of EAV was used as a negative control.
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5rUCD, and 5rVAC; Tables 4a and b). However, substitu-
tion of specific amino acids sometimes altered the neutral-
ization phenotype of individual recombinant viruses to one
or more of the MAbs or polyclonal antisera (Tables 4a and
b). For example, the 5rATCC D79N [Asp > Asn substitution
at amino acid 79 (site C)] virus was neutralized to a
considerably higher titer (>4096) with MAb 7E5 than was
its parental virus 5rATCC (512). Similarly, the exchange of
aspartic acid (Asp) to asparagine at (Asn) amino acid 49
(site A) significantly altered the neutralization of both
5rATCC D49N and 5rUCD D49N by MAbs 7E5 and 9F2,
as compared to their parental viruses (Table 4a). MAbs 7E5
and 9F2 both recognize epitopes in neutralization site D
(amino acids 99–106). Interestingly, this same amino acid
substitution (Asp > Asn-49) substantially reduced the neu-
tralization of 5rUCD D49N by MAb 1H9, which recognizes
an epitope that includes amino acids 69 (within site C) and
99–102 (within site D). Together, these data suggest that
amino acid 49 (Site A) influences the conformation of
neutralization sites C (recognized by MAb 1H9) and D
(MAbs 7E5 and 9F2). Similarly, the introduction of specific
amino acid substitutions in neutralization sites A, B, and C
sometimes altered the neutralization of the recombinant
progeny viruses by polyclonal antisera (Table 4b). Impor-
tantly, several of the single amino acid substitutions into siteC of 5rATCC changed the neutralization phenotype of the
progeny virus by some of the polyclonal equine antisera,
confirming that key neutralizing epitopes recognized by
these sera are in this region of the GP5 ectodomain.
The mutant virus (5rVAC046SDM) with amino acid
substitutions at residues 100, 104, and 106 (Gly > Ser,
Gly > Asp, Val > Met, respectively; site D) spontaneously
reverted to its original amino acid at position 100 (Gly)
during serial passage and was neutralized to a significantly
higher titer by the MAb 5G11, which recognizes an epitope
in site D (amino acids 102 and 104; Table 4a). These amino
acid changes did not alter the neutralization phenotype of
the mutant virus with any of the polyclonal antisera.
Interestingly, abrogation of the N-linked glycosylation site
at amino acid 81 did not significantly affect the neutraliza-
tion phenotype of the N81D virus (Tables 4a and b).
Similarly, two of the recombinant viruses with amino acid
substitutions at residue 49 and 67 (5rATCC D49N and
5rATCC T67A) spontaneously mutated during serial pas-
sage and lost the N-linked glycosylation site at amino acid
81 without affecting their neutralization phenotype. Togeth-
er, these data suggest that the second potential N-linked
glycosylation site at amino acid 81 does not influence the
neutralization phenotype of EAV.
In summary, data presented in this study unequivocally
prove that the GP5 ectodomain contains critical determinants
Table 3b
Neutralization titersa of polyclonal equine antisera against parental and chimeric strains of EAV
a
Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 TCID50 of virus.
Significant differences in neutralization phenotype as compared to the A45 virus are boxed.
b
Original virus strain.
c
Chimeric virus with ORF5 from the representative parental virus inserted into the pA45 infectious cDNA clone of EAV.
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neutralization sites within the N-terminal ectodomain of
EAV was confirmed by exchange of GP5 among the various
viruses and by the substitution of individual amino acids
within critical regions of GP5. The data further confirm that
individual neutralization sites (A–D) interact with one
another to form conformation-dependent epitopes, and that
the interaction of GP5 with the unglycosylated M protein
likely is critical to expression of some epitopes in neutraliz-
ing conformation (Fig. 3). The manipulation of the GP5
proteins of the various recombinant viruses often resulted in
only subtle differences in their neutralization phenotype,
analogous to differences in the neutralization phenotype of
field strains of EAV (Balasuriya et al., 1997, 1998, 1999a,
1999b; Edwards et al., 1999; Hedges et al., 1999; Westcott et
al., 1995). A high proportion of EAV-infected stallions
become persistently infected carriers and continue to shed
the virus in their semen for long periods of time (Balasuriya
et al., 1998, 1999a, 1999b, 2004; Hedges et al., 1999;
Timoney and McCollum 1993, Timoney et al., 1986,
1987). Novel genetic variants with distinct neutralization
phenotypes arise during persistent infection of carrier stal-
lions, and the altered neutralization phenotype of these
variants is correlated with amino acid changes in neutraliza-
tion sites B and C of the GP5 protein (Balasuriya et al.,
1999a, 1999b; Hedges et al., 1999). Thus, data presented inthis study are consistent with the hypothesis that variation
within the GP5 N-terminal ectodomain that is generated
during persistent infection of carrier stallions leads to the
emergence of EAV strains of different neutralization pheno-
type (Balasuriya et al., 1999a, 1999b; Hedges et al., 1999).Material and methods
Cells and viruses
Baby hamster kidney cells (BHK-21; ATCC CCL10)
were maintained in Eagle’s medium (EMEM) supplemented
with 10% fetal bovine serum (FBS; Hyclone Laboratories,
Inc.), 10% tryptose phosphate broth, and 1% penicillin and
streptomycin. Rabbit kidney 13 (RK-13; ATCC CCL 37)
cells were maintained in EMEM supplemented with 10%
calf serum (Hyclone Laboratories, Inc.) and antibiotics. The
passage histories of four field isolates of EAV (KY84, IL93,
WA97, and CA95), two prototype laboratory strains [ATCC
(ATCC VR-796), UCD], the A45 recombinant virus derived
from an EAV infectious cDNA clone (pA45), and the
modified live virus (MLV) vaccine strain (ARVAC, Fort
Dodge Laboratories) as well as two neutralization resistant
variant viruses [escape mutant (EM); EM6D10 and
DEM10B4.3] have been previously described (Table 1;
Table 4a
Neutralization titersa of MAbs against chimeric and related strains of EAV with site-specific substitutions in GP5
a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 TCID50 of virus.
Significant differences in neutralization phenotype as compared to the respective parental virus are boxed.
b Viruses with ORF5 from EAVATCC (5rATCC), MLV vaccine (5rVAC), and UCD (5rUCD) inserted into the pA45 infectious cDNA clone.
c Viruses with site-specific substitutions in ORF5 of the various parental viruses.
d MAb to the nucleocapsid (N) protein of EAV was used as a negative control.
e MAb to the nonstructural protein 1 (nsp1) of EAV was used as a negative control.
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Dobbe et al., 2001, van Dinten et al., 1997).
Monoclonal antibodies and polyclonal anti-sera
The development and characterization of a panel of 12
neutralizing monoclonal antibodies to GP5 (MAbs 5G11,
6D10, 7E5, 9F2, 10F11, 10H4, 1H7, 1H9, 5E8, 6A2, 7D4,
and 10B4) and non-neutralizing monoclonal antibodies to
the nucleocapsid protein (N; MAb 3E2) and nonstructural
protein 1 (nsp1 [MAb 12A4]) of EAV have been previouslyTable 4b
Neutralization titersa of polyclonal equine sera against chimeric and related strain
a Neutralization titers are expressed as the inverse of the antibody dilution provid
Significant differences in neutralization phenotype as compared to the respective
b Viruses with ORF5 from EAVATCC (5rATCC), MLV vaccine (5rVAC) and U
c Viruses with site-specific substitutions in ORF5 of the various parental virusesdescribed (Table 2; Balasuriya et al., 1993, 1995a, 1995b,
1997; MacLachlan et al., 1998; Wagner et al., 2003). The
production and characterization of mono-specific rabbit
antipeptide serum to nsp3 has been previously reported
(Pedersen et al., 1999). Anti-EAV strain-specific equine
sera (Table 2) were obtained by either experimental inocu-
lation of horses (EAV ATCC, KY84, IL-93, NVSL, and
030H) or by vaccination with a recombinant vaccine (anti-
GP5/M) and subsequent challenge with the KY84 field
strain (anti-GP5/M post challenge with KY84; Balasuriya
et al., 2002).s of EAV with site-specific substitutions in GP5
ing 50% protection of RK-13 cell monolayers against 200 TCID50 of virus.
parental virus are boxed.
CD (5rUCD) inserted into the pA45 infectious cDNA clone.
.
Fig. 3. Association of the GP5 and M proteins of EAVand predicted major neutralization sites in the N-terminal ectodomain of GP5. These two major envelope
proteins are covalently linked by a disulfide bond (SS) formed between Cys-8 in the M protein and the Cys-34 in the GP5 protein (Snijder et al., 2003). The
conserved cysteine residues (Cys-57, Cys-63, Cys-66, and Cys-80) in the amino-terminal ectodomain of GP5 protein are indicated, as are the predicted
conserved (Asn-56) and nonconserved (Asn-81) N-linked glycosylation sites in the GP5 ectodomain.
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The construction of the infectious cDNA clone pA45 was
described previously (Dobbe et al., 2001). In this construct,
the small natural overlap between ORFs 4 and 5 was
removed by insertion of a 24-nucleotide sequence contain-
ing a termination codon for ORF4, a unique AflII restriction
site, and the ORF5 start codon (Fig. 1). This insertion
resulted in the functional separation of ORF4 and 5, did
not interfere with virus replication, and was stable upon
repeated passaging in cell culture (de Vries et al., 2000). The
generation of the recombinant chimeric virus pA45.C2 and
deletion mutant pA45-80.4 was previously described
(Dobbe et al., 2001; Snijder et al., 2003). In the first
construct, the EAV GP5 ectodomain (amino acids 1–114)
was replaced by that of European PRRSV (amino acids 1–Table 5
Oligonucleotide primers used for RT-PCR amplification
Oligonucleotide Polarity Sequence 5V–3V
11152SD positive TCT GTG AAC TTA AGG CGG CCG CAG CATG
11152K84 positive TCT GTG AAC TTA AGG CGG CCG CAG CAT G
11152IW positive TCT GTG AAC TTA AGG CGG CCG CAG CAT G
11152VC positive TCT GTG AAC TTA AGG CGG CCG CAG CAT G
11960N negative AAA GTA ATC TAG ATA CTC ACC TAA AAT C
C211156Pc positive GGCTCAACGC TGTTATCTGT GAAC
11515Nc negative ACACATCCAA CACAACTATG CC
a Nucleotide sequence from pA45.C2 plasmid and numbered accordingly.
b EAV sequence numbered according to the pEAV030 sequence and the NotI site i
is underlined and italicized.
c Primers used in site-directed mutagenesis PCR.64), whereas in the second construct, amino acids 52–79 of
the EAV GP5 ectodomain were deleted.
A shuttle vector (pS45) containing a BglII (10704)–XhoI
(12845) fragment of the pA45 infectious cDNA clone was
used to swap ORF5 from individual EAV strains to construct
chimeric viruses. To facilitate cloning, a NotI restriction site
was inserted downstream of the AflII site in the sequence
separating ORF4 and 5 (Fig. 1). Restriction digestion of this
pS45 shuttle vector with NotI and XbaI allowed us to remove
the original ORF5 and replace it with a new ORF5 sequence
from another EAV strain, which was amplified from different
EAV strains by RT-PCR using a 5V PCR primer containing a
NotI site upstream of the ORF5 translation initiation codon
(Table 5). The 3V primer for the amplification of ORF5
included the natural XbaI site just downstream of the ORF5
sequence (nucleotide # 11949) and also included 37 nucleo-Position (nt)a
TT ATC TAT GAT TG 11152–11176a/11146–11161b
CT ATT TAT GAT TG 11152–11176a/11146–11161b
TT ATT TAT GAT TG 11152–11176a/11146–11161b
CT ATC TAT GAT TG 11152–11176a/11146–11161b
CC GTC ACC ACA AAA TGA ATC TA 11911–11960b
11137–11960a
11494–11515Nb
n each positive primer is underlined; natural XbaI site in the negative primer
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would be included in the PCR fragment. ORF5 sequences
from different EAV strains (Table 1) were RT-PCR-amplified
and digested with restriction enzymes (NotI and XbaI) and
ligated into the pS45 shuttle vector that had been digested
with the same restriction enzymes. Next, the RT-PCR-derived
insert was sequenced and the BglII –XhoI fragment
corresponding to ORFs 4 to 7 and the genomic 3V end was
transferred from chimeric pS45 shuttles to the pA45 back-
bone (Fig. 1). Site-specific nucleotide substitutions were
introduced into ORF5 of ATCC, UCD, and MLV vaccine
strains of EAV (5rATCC, 5rUCD, and 5rVAC, respectively;
Tables 1 and 6, Fig. 2b) using a standard site-directed
mutagenesis protocol described by Landt et al. (1990).
Restriction fragments containing the engineered mutation(s)
were first cloned into the pS45 shuttle vector using restriction
sites (NotI and EcoRI) and then transferred to the full-length
clone as described above.
In vitro transcription and generation of recombinant viruses
Run-off RNA transcripts were generated in vitro as
previously described from each chimeric/mutant infectious
cDNA clone after linearization with restriction enzyme XhoI
(van Dinten et al., 1997). Full-length RNA transcripts were
transfected into BHK-21 cells by electroporation as previ-
ously described (Balasuriya et al., 1999a, 1999b; van Dinten
et al., 1997). Cells were incubated at room temperature for 10
min after electroporation and mixed with 12 ml of complete
BHK-21 medium warmed to room temperature. The cells
were seeded onto 10 cm diameter tissue culture plates
(Falcon) and incubated at 37 jC for 48–72 h until cytopathic
effect (CPE) was evident. For immunofluorescence assays,
electroporated BHK-21 cells were directly seeded onto glass
coverslips and incubated at 37 jC for 12–20 h. Mono-
specific rabbit anti-peptide serum to the nsp3, and MAb
3E2 to the N protein were used to detect virus replicationTable 6
Oligonucleotide primers used for site-directed mutagenesis of ORF5
Oligonucleotide
name
Polarity Sequence 5V–3Va
D49N N negative AGCAGTGTGCTCATtATATCGCAGCAAATTG
K61Q N negative GTGCAATACCAACAGGTTTgACTGGCGGAA
T67A N negative CTGTTCGTCCAGGAATGcGCAATACCAACA
E71D N negative CCAAACGTGATAATCTGaTC GTCCAGGAAT
D79N N negative CGCGTAGGTGTCATTACAATtGGTTCCAAA
N81D N negative CCGCGTAGGTGTCATcACAATCGGTTCCAA
A85S N negative CTCAGCAACTGGGACCGaGTAGGTGTCATT
GGV046SDM N negative GTAAATAAAAGGGGGCAtGTCAtCAAACAGC
a Mutated nucleotide is shown in lower case letter.
b Nucleotides are numbered according to the published sequence of EAV030 viru
c Positive sense nucleotide change.
d Abrogation of N-linked glycosylation site at position 81.and expression of specific proteins in the electroporated
BHK-21 cells by immunofluorescence staining as previously
described (van der Meer et al., 1998). Tissue culture fluid
(TCF) was harvested and centrifuged at 400  g for 10 min
at 4 jC. Each chimeric/mutant virus was passaged three more
times on BHK-21 cells to make working stocks and the titer
of each virus was determined as tissue culture infectious
doses (TCID50) using RK-13 cells as the indicator cells. The
virus titers of the stocks ranged from 104.5 to 106.5 TCID50
units per 50 Al.
RT-PCR amplification and sequencing of ORF5 of
recombinant viruses
The authenticity of the ORF5 insert in each chimeric/
mutant virus stock was determined by RT-PCR amplification
and sequencing of the entire gene fromRNA that was isolated
from TCF from passage three of each virus (Balasuriya et al.,
1999a, 1999b). Briefly, RNA was directly isolated from the
TCF using the QIAmp viral RNA isolation kit (Qiagen). The
purified RNAwas treated with DNase I (Ambion) for 30 min
at 37 jC to remove any contaminating plasmid DNA before
RT-PCR amplification. The RT-PCR amplification and se-
quencing of ORF5 was done as previously described (Bala-
suriya et al., 1995a, 1995b; Hedges et al., 1996). Sequence
data were collected and edited with an ABI 377 Automatic
Sequencer (Applied Biosystems) according to the manufac-
turer’s instructions. Nucleotide and amino acid sequence data
were analyzed using Sequencher 3.0 (Gene Codes Corp.) and
HIBIO MacDNASIS Pro Version 3.5 software (Hitachi
Software Engineering Co., Ltd.).
Microneutralization assay
All viruses were characterized by microneutralization
assay as previously described (Balasuriya et al., 1995a,
1995b, 1997). Neutralization titers were determined for eachPosition (nt)b Nucleotide
changec
Amino acid
change
Mutagenesis
of ORF5
from
11274–11304 11290 G > A 49 D > N ATCC and
UCD
11316–11345 11326 A > C 61 K > Q ATCC
11332–11361 11344 A > G 67 T > A ATCC
11346–11375 11358 A > T 71 E > D ATCC
11371–11401 11380 G > A 79 D > N ATCC
11372–11401 11386 A > G 81 N > Dd ATCC
11386–11415 11398 G > T 85 A > S ATCC
ACACtGTA 11440–11478 11443 G > A 100 G > S vaccine
11456 G > A 104 G > D
11461 G > A 106 V > M
s.
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EAV using all of the various MAbs and polyclonal equine
antisera (Table 2).Acknowledgments
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